Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform
Authors:
- 31 March 2021
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Radiopharmaceuticals
- Vol. 14 (1) , 23-36
Abstract
Background: Theranostic oncology combines therapy and diagnosis and is a new field of medicine that specifically targets the disease by using targeted molecules to destroy the cancerous cells without damaging the surrounding healthy tissues. Objective: We aimed to develop a tool that exploits enzymatic TQ release from glucuronide (G) for the imaging and treatment of lung cancer. We added magnetic nanoparticles (MNP) to enable magnetic hyperthermia and MRI, as well as 131I to enable SPECT imaging and radionuclide therapy. Methods: A glucuronide derivative of thymoquinone (TQG) was enzymatically synthesized and conjugated with the synthesized MNP and then radioiodinated with 131I. New Zealand white rabbits were used in SPECT and MRI studies, while tumor modeling studies were performed on 6–7- week-old nude mice utilized with bioluminescence imaging. Results: Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) spectra confirmed the expected structures of TQG. The dimensions of nanoparticles were below 10 nm and they had rather polyhedral shapes. Nanoparticles were radioiodinated with 131I with over 95% yield. In imaging studies, in xenograft models, tumor volume was significantly reduced in TQGMNP-treated mice but not in non-treated mice. Among mice treated intravenously with TQGMNP, xenograft tumor models disappeared after 10 and 15 days, respectively. Conclusion: Our findings suggest that TQGMNP in solid, semi-solid and liquid formulations can be developed using different radiolabeling nuclides for applications in multimodality imaging (SPECT and MRI). By altering the characteristics of radionuclides, TQGMNP may ultimately be used not only for diagnosis but also for the treatment of various cancers as an in vitro diagnostic kit for the diagnosis of beta glucuronidase-rich cancers.Keywords
Funding Information
- NIH/ NCI Cancer Center (P30 CA008748)
- Turkish Scientific Research Council- Health Sciences Research Support Group (113S922)
This publication has 36 references indexed in Scilit:
- Review on Molecular and Therapeutic Potential of Thymoquinone in CancerNutrition and Cancer, 2010
- Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathwayBritish Journal of Pharmacology, 2010
- Lipophilicity determination of N-( benzothiazol-2-yl )-α-amino alkyl phosphonic diesters by RP-HPLC and RP-HPTLCChinese Journal of Chemistry, 2010
- Enzymatic Synthesis of Uracil Glucuronide, Labeling with 125/131 I, and In Vitro Evaluation on Adenocarcinoma CellsCancer Biotherapy and Radiopharmaceuticals, 2010
- Monitoring with a non-invasive bioluminescent in vivo imaging system of pleural metastasis of lung carcinomaLung Cancer, 2009
- Clearance Properties of Nano-Sized Particles and Molecules as Imaging Agents: Considerations and CaveatsNanomedicine, 2008
- Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imagingCell and tissue research, 2004
- PROTECTIVE EFFECT OF THYMOQUINONE AGAINST DOXORUBICIN–INDUCED CARDIOTOXICITY IN RATS: A POSSIBLE MECHANISM OF PROTECTIONPharmacological Research, 2000
- The Role of β-Glucuronidase in Drug Disposition and Drug Targeting in HumansClinical Pharmacokinetics, 1997
- Effective targeting of magnetic radioactive90Y-microspheres to tumor cells by an externally applied magnetic field. Preliminary in vitro and in vivo resultsNuclear Medicine and Biology, 1995